FDA Approves Zidesamtinib for ROS1 Lung Cancer - Summary - MDSpire

FDA Approves Zidesamtinib for ROS1 Lung Cancer

Phase 1/2 ARROS-1 data showed a 44% objective response rate, with most responses ongoing at 6 months.

  • By

  • Kathryn Wighton

  • July 23, 2026

  • 2 min

Share

Original Source(s)

FDA Approves Zidesamtinib for ROS1 Lung Cancer

  • by Kathryn Wighton

  • July 23, 2026

Related Content

Photon-Counting CT Improves Tumor Detection

Lower-dose scans were associated with improved tumor feature detection and fewer adverse events compared with standard imaging

AI Drafts Cut Radiograph Reporting Time

Prospective cohort study found faster documentation, with no statistically significant difference in peer-reviewed report quality

Lung NODES Improves Nodal Assessment

Community programs showed the largest gains in compliance with a surgical staging standard following participation in the Lung NODES collaborative.